换一批A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.
第一作者：
David B,Yaden
第一单位：
Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
作者：
David B,Yaden [1]
;
Marianna,Graziosi [2]
;
Alexa M,Owen [3]
;
Gabrielle,Agin-Liebes [4]
;
Scott T,Aaronson [5]
;
Katja Ehrmann,Allen [6]
;
Frederick S,Barrett [7]
;
Michael P,Bogenschutz [8]
;
Robin,Carhart-Harris [9]
;
Terence H W,Ching [10]
;
Mary P,Cosimano [11]
;
Alicia,Danforth [12]
;
Alan K,Davis [13]
;
Albert,Garcia-Romeu [1]
;
Roland,Griffiths [1]
;
Charles S,Grob [12]
;
Gerhard,Gründer [14]
;
Natalie,Gukasyan [15]
;
Keith G,Heinzerling [16]
;
Peter S,Hendricks [17]
;
Friederike,Holze [18]
;
David M,Horton [19]
;
Matthew W,Johnson [20]
;
Benjamin,Kelmendi [10]
;
Stephanie,Knatz Peck [21]
;
Michael,Koslowski [22]
;
Matthias E,Liechti [18]
;
Lea J,Mertens [14]
;
Francisco A,Moreno [23]
;
Sandeep M,Nayak [1]
;
Christopher R,Nicholas [19]
;
Katrin H,Preller [24]
;
Nathalie M,Rieser [24]
;
Stephen,Ross [8]
;
Karina,Sergi [16]
;
Jordan,Sloshower [10]
;
Lukasz,Smigielski [25]
;
Dea Siggaard,Stenbæk [26]
;
Franz X,Vollenweider [24]
;
Brandon,Weiss [1]
;
Max,Wolff [27]
;
Mary Elizabeth,Yaden [1]
作者单位：
Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
[1]
Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.;Department of Clinical Psychology, Hofstra University, Hempstead, New York, USA.
[2]
Smith College School for Social Work, Northampton, Massachusetts, USA.
[3]
Department of Psychiatry, University of California, San Francisco, California, USA.;Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt, Towson, Maryland, USA.
[4]
University of Maryland School of Medicine, Baltimore, Maryland, USA.;University of Arizona, Tucson, Arizona, USA.
[5]
Department of Psychological & Brain Sciences, Krieger School of Arts & Sciences, Johns Hopkins University, Baltimore, Maryland, USA.
[6]
Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.;Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.;Department of Psychiatry, NYU Langone Center for Psychedelic Medicine, NYU Grossman School of Medicine, New York, New York, USA.
[7]
Department of Neurology, University of California San Francisco, San Francisco, California, USA.
[8]
Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt, Towson, Maryland, USA.
[9]
Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.
[10]
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
[11]
The Lundquist Institute at the Harbor-UCLA Medical Center, Torrance, California, USA.
[12]
Center for Psychedelic Drug Research and Education, College of Social Work, The Ohio State University, Columbus, Ohio, USA.;Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
[13]
Central Institute of Mental Health, Department of Molecular Neuroimaging, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.;German Center for Mental Health (DZPG), Partner Site Mannheim, Mannheim, Germany.
[14]
New York State Psychiatric Institute, Columbia University Medical Center, New York, New York, USA.
[15]
Treatment and Research In Psychedelics (TRIP) Center, Pacific Neuroscience Institute at Providence Saint John's Health Center, Santa Monica, California, USA.
[16]
Department of Psychiatry and Behavioral Neurobiology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
[17]
Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.;Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
[18]
Department of Family Medicine and Community Health, University of Wisconsin, Madison, Wisconsin, USA.
[19]
Center of Excellence for Psilocybin Research and Treatment, Sheppard Pratt, Townson, Maryland, USA.;Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
[20]
Department of Psychiatry, University of California San Diego, San Diego, California, USA.
[21]
Department of Psychiatry and Psychotherapy, Charité CCM-Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.;Iméra Institute of Advanced Studies, Aix Marseille University, Marseille, France.
[22]
College of Medicine Tucson, University of Arizona, Tucson, Arizona, USA.
[23]
Department of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic Zurich, University of Zurich, Zurich, Switzerland.
[24]
Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland.
[25]
Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Denmark.;Department of Psychology, Copenhagen University Clinic for Psychedelic Research, University of Copenhagen, Copenhagen, Denmark.
[26]
MIND Foundation gGmbH, Berlin, Germany.;Department of Psychiatry and Psychotherapy, Charité CCM-Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
[27]
DOI
10.1089/psymed.2024.0019
PMID
40351554
发布时间
2025-07-08
- 浏览0
Psychedelic medicine (New Rochelle, N.Y.)
Psychedelic medicine (New Rochelle, N.Y.)
2025年3卷1期
1-18页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
